bill van <
bil...@delete.shaw.ca> wrote in
news:billvan-ED70D4...@shawnews.vc.shawcable.net:
I'm sympathetic to that point of view. On a somewhat related note, the NY
Times had an interesting article yesterday about a key regulator of cancer
treatments and issues about the pace of approvals.
http://nyti.ms/1Jl8Xh0
It's obviously very easy for treatments to get bogged down in the approval
process.
I think this is a good couple of pieces by Michael Specter from
newyorker.com on some of the issues --
http://tinyurl.com/pk3d6ou
http://tinyurl.com/p9anb4j
I'm not saying the research should be banned, but we really don't have a
good regulatory framework in place for handling it. And just as it's easy
to demogogue against genetic research, it's also extremely to do the same
thing for it.
The first article describes one possible approach to eliminating Lyme
Disease by rewriting the genes of wild mice to eliminate their ability to
act as hosts. It includes a telling sentence:
Esvelt [the researcher] stressed that such an approach would
become possible only after much more research and a
lengthy series of public discussions on the risks and benefits
of the process.
The first part of that sentence is true -- much more work is needed. But
the second is not -- there is little forcing public discussions on risks
and benefits, and it would be fairly trivial for agribusiness lobbyists to
gain extremely relaxed standards if a Republican was elected president, and
it could also happen under a Democrat, though somewhat less likely.
That need for public discussion is the point of the second Michael Specter
piece. Monsanto did early GMO work largely in secret and acted with a
great lack of transparency, and to this day sees the issue through the lens
of PR and trade secrecy rather than science. That lack of open discussion
is a major reason for the backlash, but I see little sign that future
agricultural or medical business interests will act very differently.
We also don't have a good legal framework for handling related IP issues,
and I think it's worth wondering what happens if key developments get
walled off by patent owners -- we may well end up with a sympathetic
government structure enforcing private regulation of cancer treatments, for
example. As the Martin Shkreli case shows, it's pretty easy for companies
to game the current system to control the supply of essential drugs, and in
the US the courts, patent system and Congress have been extremely bad at
figuring out current IP issues, which isn't encouraging for what they'll do
with CRISPR-related research.